特瑞普利单抗在膀胱肿瘤综合治疗中的疗效和安全性分析

Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors

目的:评价真实世界中特瑞普利单抗在膀胱尿路上皮癌(bladder urothelial carcinoma,UBC)及特殊类型膀胱肿瘤(atypical bladder tumor,ABT)综合治疗中的疗效及相关安全性。方法:纳入46例手术+特瑞普利单抗综合治疗的膀胱肿瘤患者(32例尿路上皮癌、14例特殊类型肿瘤)的资料,统计分析治疗期间出现的治疗相关不良反应发生率及疗效评估。结果:分组:尿路上皮癌患者32例,特殊类型膀胱肿瘤14例,在使用特瑞普利单抗的综合治疗中患者整体复发率为15.2%,46例患者常见不良反应包括皮肤瘙痒(17.4%),甲状腺功能异常(15.2%),食欲下降(10.9%)等,其中3~4级不良反应发生有14例,占总不良反应的36.8%。结论:特瑞普利单抗在UBC和ABT的综合治疗中的疗效显著,整体安全可控,但应警惕不良反应。

Objective:To evaluate the efficacy and safety of toripalimab in the comprehensive treatment of bladder urothelial carcinoma(UBC)and atypical bladder tumor(ABT)in real-world settings.Methods:Data from 46 patients with bladder tumors(32 with UBC and 14 with ABT)who underwent surgery combined with toripalimab treatment were included for analysis of occurrence rates of treatment-related adverse reactions and efficacy during the treatment period.Results:For the 32 patients with UBC and 14 patients with ABT,the overall recurrence rate was 15.2%after the comprehensive treatment with toripalimab.Common adverse reactions ob-served in the 46 patients included pruritus(17.4%),thyroid dysfunction(15.2%),and decreased appetite(10.9%).There were 14 events of grade 3-4 adverse reactions,accounting for 36.8%of the total adverse events.Conclusion:Toripalimab demonstrates signifi-cant efficacy and overall manageable safety in the comprehensive treatment of UBC and ABT.However,vigilance is necessary for ad-verse reactions.